CARM CARISMA THERAPEUTICS INC revenue, earnings and financials
For the quarter ended September 30, 2025, CARISMA THERAPEUTICS INC reported revenue of $45.3M (up 1232.4% from a year earlier), net income of $44.7M and diluted EPS of $1.07; for the fiscal year ended December 2024 revenue was $19.6M, up 31.5% on the year before.
CARM annual revenue and earnings
- Fiscal year ended Dec 2024: revenue $19.6M, gross profit n/a, operating income −$62.2M, net income −$60.5M (margin -308.6%), EPS −$1.46
- Fiscal year ended Dec 2023: revenue $14.9M, gross profit n/a, operating income −$88.7M, net income −$86.9M (margin -583.1%), EPS −$2.59
- Fiscal year ended Dec 2022: revenue $9.80M, gross profit n/a, operating income −$56.2M, net income −$61.2M (margin -624.8%), EPS −$28.77
- Fiscal year ended Dec 2021: revenue $26.5M, gross profit n/a, operating income −$8.55M, net income −$336K (margin -1.3%), EPS $0.00
CARM quarterly revenue and earnings
- Quarter ended Sep 30, 2025: revenue $45.3M (up 1232.4% year over year), net income $44.7M, EPS $1.07
- Quarter ended Jun 30, 2025: revenue n/a, net income −$9.77M, EPS −$0.23
- Quarter ended Mar 31, 2025: revenue $3.70M (up 8.8% year over year), net income −$9.27M, EPS −$0.22
- Quarter ended Dec 31, 2024 (from the annual report): revenue $3.60M (down 16.3% year over year), net income −$17.6M, EPS −$0.42
- Quarter ended Sep 30, 2024: revenue $3.40M (down 10.5% year over year), net income −$12.7M, EPS −$0.31
- Quarter ended Jun 30, 2024: revenue $9.20M (up 155.6% year over year), net income −$11.2M, EPS −$0.27
- Quarter ended Mar 31, 2024: revenue $3.40M (up 6.3% year over year), net income −$19.0M, EPS −$0.46
- Quarter ended Dec 31, 2023 (from the annual report): revenue $4.30M (up 16.3% year over year), net income −$21.0M, EPS $0.36
- Quarter ended Sep 30, 2023: revenue $3.80M (up 47.4% year over year), net income −$21.4M, EPS −$0.53
- Quarter ended Jun 30, 2023: revenue $3.60M (up 33.2% year over year), net income −$19.9M, EPS −$0.49
- Quarter ended Mar 31, 2023: revenue $3.20M (up 289.3% year over year), net income −$24.6M, EPS −$1.93
- Quarter ended Dec 31, 2022 (from the annual report): revenue $3.70M (down 81.5% year over year), net income −$16.7M, EPS −$7.71
- Quarter ended Sep 30, 2022: revenue $2.58M, net income −$18.3M, EPS −$8.37
- Quarter ended Jun 30, 2022: revenue $2.70M (up 21.0% year over year), net income −$14.8M, EPS −$7.20
- Quarter ended Mar 31, 2022: revenue $822K (down 80.9% year over year), net income −$11.3M, EPS −$5.49
- Quarter ended Dec 31, 2021 (from the annual report): revenue $20.0M, net income $8.94M, EPS $0.14
- Quarter ended Sep 30, 2021: revenue $0, net income $71.7M, EPS $0.36
- Quarter ended Jun 30, 2021: revenue $2.23M, net income −$25.4M, EPS −$0.15
- Quarter ended Mar 31, 2021: revenue $4.31M, net income −$55.5M, EPS −$0.35
CARM cash flow, buybacks and dividends
- Fiscal year ended Dec 2024: operating cash flow −$59.9M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$81.2M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$5.12M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$68.9M, share buybacks n/a
CARM balance sheet
- Sep 30, 2025: cash $2.78M, total assets $6.55M, total liabilities $7.42M, shareholders' equity n/a
- Jun 30, 2025: cash $2.00M, total assets $5.01M, total liabilities $51.0M, shareholders' equity n/a
- Mar 31, 2025: cash $7.74M, total assets $16.0M, total liabilities $52.6M, shareholders' equity n/a
- Dec 31, 2024: cash $17.9M, total assets $30.5M, total liabilities $58.4M, shareholders' equity n/a
- Sep 30, 2024: cash $26.9M, total assets $42.1M, total liabilities $53.2M, shareholders' equity n/a
- Jun 30, 2024: cash $40.4M, total assets $59.3M, total liabilities $59.0M, shareholders' equity n/a
- Mar 31, 2024: cash $56.5M, total assets $73.8M, total liabilities $62.9M, shareholders' equity n/a
- Dec 31, 2023: cash $77.6M, total assets $89.6M, total liabilities $63.0M, shareholders' equity $26.5M
What is CARM's revenue?
CARISMA THERAPEUTICS INC reported $19.6M of revenue for the fiscal year ended December 2024.
Is CARM profitable?
Yes. CARISMA THERAPEUTICS INC earned $8.04M over the last four quarters.
What is CARM's EPS?
Diluted earnings per share over the last four quarters were $0.20; $1.07 in the latest quarter.